MedTrace Logo

Zinc Sulphate in Treatment Fibrosis in HBV Patient Receiving Antiviral Therapy

NCT07145268 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2025-08-28

No results posted yet for this study

Summary

This study aims to investigate the possible safety and efficacy of Zinc sulphate as antifibrotic agent in chronic HBV patient receiving antiviral therapy.

Conditions

  • Liver Fibroses
  • HBV (Hepatitis B Virus)

Interventions

DRUG

Entecavir (ETV)

Standard antiviral therapy with Entecavir 0.5 mg orally once daily for 6 months."(control group)

DRUG

Zinc (zinc sulphate)

Zinc sulfate 220 mg orally once daily (50 mg elemental zinc) in addition to Entecavir 0.5 mg, for 6 months."

Sponsors & Collaborators

  • Tanta University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-01
Primary Completion
2026-09-01
Completion
2026-09-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07145268 on ClinicalTrials.gov